Livingston W K, Elliott A M, Cobbs C G
Antimicrob Agents Chemother. 1981 Jan;19(1):114-6. doi: 10.1128/AAC.19.1.114.
The in vitro activities of N-formimidoyl thienamycin (MK0787) and nine other antibiotics were tested against 129 clinical isolates, including 71 of enterococci, 34 of Staphylococcus epidermidis, 17 of Pseudomonas aeruginosa, and 7 of Serratia marcescens. These isolates exhibited a variety of resistant patterns: 97% of the enterococci were resistant to moxalactam; 71 and 81% of the S. epidermidis isolates were resistant to methicillin and penicillin, respectively; 47, 53, and 53% of the P. aeruginosa isolates were resistant to carbenicillin, cefotaxime, and moxalactam, respectively; and all S. marcescens isolates were resistant to amikacin, gentamicin, and tobramycin. With respect to concentrations required to inhibit growth of 90% of the isolates, N-formimidoyl thienamycin was more active than any compound tested. Determination of the concentration required to inhibit growth of 50% of the isolates showed N-formimidoyl thienamycin to be more active than any other agent against S. epidermidis, S. marcescens, and enterococci, but against Pseudomonas isolates it was less active than amikacin, gentamicin, and tobramycin. This preparation is potentially useful for patients with serious infection caused by resistant bacteria; enterococcal and S. epidermidis endocarditis infections may be special situations which merit clinical trials.
对N-甲酰亚胺硫霉素（MK0787）和其他九种抗生素进行了体外活性测试，受试对象为129株临床分离菌，其中包括71株肠球菌、34株表皮葡萄球菌、17株铜绿假单胞菌和7株粘质沙雷氏菌。这些分离菌呈现出多种耐药模式：97%的肠球菌对莫拉卡坦耐药；71%和81%的表皮葡萄球菌分离菌分别对甲氧西林和青霉素耐药；47%、53%和53%的铜绿假单胞菌分离菌分别对羧苄青霉素、头孢噻肟和莫拉卡坦耐药；所有粘质沙雷氏菌分离菌对阿米卡星、庆大霉素和妥布霉素均耐药。就抑制90%分离菌生长所需的浓度而言，N-甲酰亚胺硫霉素比所测试的任何化合物都更具活性。对抑制50%分离菌生长所需浓度的测定表明，N-甲酰亚胺硫霉素对表皮葡萄球菌、粘质沙雷氏菌和肠球菌的活性高于任何其他药物，但对铜绿假单胞菌分离菌的活性低于阿米卡星、庆大霉素和妥布霉素。这种制剂可能对耐药菌引起的严重感染患者有用；肠球菌和表皮葡萄球菌性心内膜炎感染可能是值得进行临床试验的特殊情况。
